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and Ljiljana Dimitrijević
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ABSTRACT
Results are presented concerning our attempts to create a suitable model system for studying the con-
nection between microbial antigen (micAg), autoimmunity and autoimmune disease on the basis of
hyper-immunization and application of micAg in different contexts. Our research was focused on tetanus
toxoid (TTd) as a model micAg. Non-pretreated and complete Freund’s adjuvant pretreated BALB/c mice
were immunized with high doses of TTd mixed with glycerol or aluminum hydroxide as adjuvants. The
main aims of the experiments were to evaluate the properties of induced humoral immune responses,
evaluate the pathological potential of induced immune responses and determine possible correlations
between the properties of a humoral immune response and its pathological potential. The production
of TTd-specific and self-reactive β2-glycoprotein I (β2-GP I)-specific antibodies (Abs) was detected in all
groups but with specific, context-related properties. Analysis of pregnancy-related pathology (anti-β2-
GP I Abs-associated) showed differences in the pathological potential of the induced immune response.
It was demonstrated that severity of pathology is positively correlated to the abundance of IgG that recog-
nizes β2-GP I adsorbed onto phosphatidylserine, and to IgG affinity. Furthermore, it was demonstrated
that molecular mimicry, which results in generation of anti-β2-GP I Abs upon TTd immunization, is
necessary but not sufficient for the development of pregnancy-related pathology.
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Various data that connect exposure to micAg, during in-
fections (1–4) and vaccinations (5–8), to autoAb produc-
tion have been published in recent years. Among the pos-
sible mechanisms that contribute to autoAb generation,
the most cited mechanisms are molecular mimicry (9, 10)
and polyclonal cell activation (11, 12). Available data show
that long-term stimulation by micAg is accompanied by
augmentation of self-reactivity, but not by obvious induc-
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Marijana Stojanović, Institute of Virology, Vaccines and Sera – Torlak, Vojvode Stepe 458, 11152 Belgrade, Serbia.
Tel: +381 11 39 75 501; fax: +381 11 24 67 465; email: mazes@eunet.yu
Received 13 August 2008; revised 18 September 2008; accepted 2 October 2008
List of Abbreviations: Ab, antibody; Ag, antigen; Al, aluminium hidroxid; APS, anti-phospholipid syndrome; autoAb, autoantibody; β2-GP I, β2-
glycoprotein I; CFA, complete Freund’s adjuvant; CFA//, CFA-pretreated; glyc, glycerol; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IL,
interleukin; KSCN, potassium thiocyanate; micAg, microbial antigen; nc, normal age-matched control; no//, non-pretreated; NoF, number of full-term
fetuses; NoFR, number of fetal resorptions; OPD, o-phenylenediamine; PI, percentage of inhibition; PS, phosphatidylserine; SCN−, thiocyanate ion;
[SCN−], SCN− concentration; [SCN−]50%, [SCN−] that induced a 50% reduction of initial absorbance; Th, T helper; TLR, Toll-like receptor; TTd, tetanus
toxoid; TTd/Al, TTd mixed with 2% aluminum hydroxide; TTd/glyc, TTd mixed with 2.5 M glycerol.
tion of autoimmune diseases (13). Hence, we have tried
to create a model system for studying the connection be-
tween micAg, autoimmunity and autoimmune disease on
the basis of hyper-immunization and application of micAg
in different contexts.
With the intention of creating a suitable model system,
we focused our research on TTd, a chemical derivative
of tetanus toxin, as a model antigen. As a single protein
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Fig. 1. Immunization and bleeding
schedules.
molecule, TTd is less complex and more easily charac-
terized than bacterial cell or viruses, but at the same time
fulfills the criteria for induction of autoimmunity. Tetanus
toxoid and several serum proteins have similar structure
at either the three-dimensional level (IL-1α, IL-1β) (14)
or the level of short peptide sequence homology (β2-
GP I) (15) and laminin (16)). This structural similarity
favors the role of TTd in autoimmunity, with molecu-
lar mimicry as the mechanism. These facts serve as the
basis for tracking anti-β2-GP I and anti-laminin Abs as
markers of a self-reactive immune response following TTd
immunization.
In the murine immune system, anti-laminin Abs have
obvious pathological attributes (17), whereas anti-β2-GP
I Abs can exert both beneficial (playing a homeostatic role)
and deleterious effects, depending on their concentration,
isotopic characteristics, affinity and fine epitope speci-
ficity (18). The pathological anti-β2-GP I Abs represent a
molecular substrate of the APS, a systemic autoimmune
disorder characterized by arterial and venous thrombosis
and/or pregnancy-related pathology (19).
To induce maximal immune system activation, we im-
munized BALB/c mice with high concentrations of TTd
(20). Aluminum hydroxide or glycerol were used as adju-
vants to promote the humoral (21–23) and cellular (24)
arms of the immune response, respectively. TTd immu-
nizations were performed on non-pretreated or pretreated
mice (single dose of CFA injected subcutaneously one
week before the start of immunization). By combining
specific TTd immunization (with glycerol or aluminum
hydroxide as adjuvants) with CFA pretreatment, we were
able to hyper-stimulate both arms of the immune system
simultaneously (25).
The main aims of the experiments were to 1) evaluate
properties of humoral immune responses induced by TTd
as applied in different contexts; 2) evaluate the patholog-
ical potential of the induced immune responses and 3)
determine possible correlations between the properties
of the humoral immune response and its pathological
potential. Obtained results clearly demonstrated that the
properties of induced immune responses were context-
dependent, thus providing a basis for the establishment
of a new animal model to examine the underlying mech-
anisms of the association between micAg, autoimmunity
and autoimmune disease.
MATERIALS AND METHODS
Immunization and bleeding schedules
Ten-week-old BALB/c female mice were used in the ex-
periments. Immunization and bleeding schedules are pre-
sented in Figure 1. Briefly, pretreatments (single dose of
CFA injected subcutaneously) were performed one week
before the first TTd application. Non-pretreated and CFA-
pretreated mice were immunized with high doses of TTd
(Institute, Torlak, Belgrade) mixed with either 2.5 M glyc-
erol (TTd/glyc) or 2% aluminum hydroxide (TTd/Al) as
adjuvants (three times at 2-week intervals, 500 μg/ml
TTd per dose, 200 μl/mouse, subcutaneously). Sixteen
weeks after the third dose, one additional dose of TTd was
administered with an appropriate adjuvant (the booster
dose). TTd used for immunization had passed the tests of
specific and reversed toxicity according to European Phar-
macopoeia requirements. According to the pretreatments
and immunization protocols applied, the whole experi-
mental mice population was divided into four groups (15
mice per group). In addition, a group (10 mice) of non-
treated BALB/c mice was used as normal age-matched
controls.
Samples of blood sera were collected by bleeding from
the retro-orbital plexus before any intervention (normal
sera), and subsequently at 2-week intervals during a pe-
riod of more than 3 months and 1 week after the booster
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TTd dose application. The collected sera were comple-
ment depleted, aliquoted and stored at –20 ◦C until used
for analyses. For serological assays, individual sera or sera
pools (mixtures containing the same volume of sera ob-
tained from identically immunized mice at the same time
point in relation to the start of treatment) were used as
samples. The main check points were before any inter-
vention (normal sera), 1 week after the third TTd dose
(check point A), 11 weeks after the third TTd dose (check
point B) and 1 week after the booster TTd dose application
(check point C). Corresponding sera pools were assigned
as normal, A, B and C, respectively.
All animal experimentation was conducted in accor-
dance with the local “Guiding Principles for the Care and
Use of Laboratory Animals”, conformed with the provi-
sions of the Declaration of Helsinki and was approved by
the Animal Institutional Care and Use Committee at the
Institute, Torlak, Belgrade.
Isolation of β2-GP I from human plasma
β2-GP I, which was used for serological tests, was isolated
from human plasma. Briefly, 70% perhloric acid (2.5 ml)
was added to human plasma (100 ml) and stirred for
15 min on ice. After centrifugation (15 min, 13 000 g , 4◦C;
3K18 Sigma Laboratory Centrifuge, Osterode, Germany),
the supernatant was collected and the pH neutralized. Pre-
cipitation of β2-GP I was performed by addition of am-
monium sulfate to 65% saturation. Following incubation
(stirred for 30 min on ice) and centrifugation (15 min,
13 000 g , 4◦C), the pellet was resuspended in 0.05 M
NaCl/0.05 M HEPES, at pH 7, and dialyzed against the
same solution over night at 4◦C. Isolation of β2-GP I
was done by ion-exchange chromatography on a Mono S
column (Pharmacia Amersham, Uppsala, Sweden) con-
nected to a high-performance liquid chromatography sys-
tem (ÄKTA Purifier; Pharmacia Amersham). The bound
β2-GP I was eluted by a linear gradient of NaCl concen-
tration (0.05–0.5 M), checked for purity by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (10%–15%
polyacrylamide gel; Phast System; Pharmacia Amersham)
and identified as β2-GP I by immune-blotting analysis,
with the use of commercially available mouse anti-human
β2-GP I IgG1 (clone 5F7; ICN Biomedicals, Aurora, IL,
USA).
Indirect ELISA
Detection of sera Abs specific for TTd, β2-GP I or
laminin was performed by indirect ELISA. In all cases the
ExtrAvidin-peroxidase/OPD system (Sigma, Steinheim,
Germany) was used to visualize Ag–Ab interactions. Ab-
sorbance was monitored at 492 and 692 nm (A492/692).
The cut-off value for each system was defined according
to the A492/692 read in “negative control” wells (1% BSA;
w/v in PBS as a sample) plus 3× SD. Serum samples were
considered positive when the A492/692 value exceeded the
cut-off value.
Detection of Abs specific for TTd and β2-GP I
ELISA plates (MaxiSorp; Nunc, Roskilde, Denmark) were
covered (50 μl/well) with appropriate Ag – TTd (1 μg/ml
TTd in PBS) or β2-GP I (10 μg/ml β2-GP I in PBS) by
overnight adsorption at 4◦C. One percent BSA (w/v) in
PBS (1% BSA/PBS) was used for blocking for 2 hours at
room temperature. The blocking, as well as all subsequent
ELISA steps, were followed by washing with 0.05% (v/v)
Tween 20 in PBS (four times, 200 μl/well). Appropriately
diluted serum samples were incubated for 1 hour at room
temperature. Ag-specific Ab binding was detected with
the following biotin-labeled Abs (used according to the
manufacturer’s instructions): anti-mouse IgM (Cat. No.
B-9265; Sigma, St. Louis, MO, USA), anti-mouse IgG (Cat.
No. B-7401; Sigma, Steinheim, Germany), anti-mouse
IgG1 (clone LO-MG1–2; ICN Biomedicals) or anti-mouse
IgG2a (clone LO-MG2a-3; ICN Biomedicals). An appro-
priate biotin-labeled Ab (50 μl/well) was incubated for
1 hour at room temperature.
Serum samples were diluted 1:800, except for detec-
tion of anti-TTd IgG (1:1000) and anti-β2-GP I subclass
evaluation (1:500).
Detection of sera IgG specific for β2-GP I adsorbed onto PS
PS (Sigma, Steinheim, Germany) (10 μg/ml, 50 μl/well)
was immobilized onto ELISA plates (PolySorp; Nunc)
by evaporation at room temperature. Then, β2-GP I
(10 μg/ml, 50 μl/well) was coated by overnight incuba-
tion at 4◦C. The steps that followed were the same as those
described for detection of anti-β2-GP I Abs.
Detection of sera IgG specific for mouse laminin
Mouse laminin (Sigma, St. Louis, MO, USA) (10 μg/ml,
50 μl/well) was adsorbed onto microtiter plates (Max-
iSorp; Nunc) for 4 hours at 37◦C. The plates were then
washed (three times, 200 μl/well PBS) and blocked with
1% BSA/PBS. Samples (sera diluted 1:200 in 1% w/v BSA,
0.05% v/v Tween 20 in PBS) were added to the plates af-
ter washing (four times, 200 μl/well 0.05% v/v Tween 20
in PBS) and incubated overnight at 4◦C. Bound IgG was
detected after incubation with biotin-labeled anti-mouse
IgG (Sigma, Steinheim, Germany).
Competitive ELISA for detection of Y7
natural idiotope concentration changes
in sera of immunized mice
For the measurement of Y7 expression, two mono-
clonal Abs were used: biotin-labeled F(ab)2 of the mouse
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monoclonal anti-idiotopic antibody Y7 (F(ab)2 Y7-B) and
Y7+ human monoclonal Ab IgM DJ. The Y7 concentra-
tion was estimated via inhibition of F(ab)2 Y7-B binding
to IgM DJ adsorbed onto plastic. IgM DJ was bound on a
microtiter plate (MaxiSorp; Nunc) (50 μl/well) at a con-
centration of 500 ng/ml. The F(ab)2 Y7-B (200 ng/ml)
was mixed with mice sera diluted in 1% w/v BSA in
PBS solution (final dilution of 1:100), pre-incubated for
1 hour at 25◦C in a water bath and further incubated
with IgM DJ coated on the microplate walls. ExtrAvidin-
peroxidase/OPD was used as a detection system. The PI
was calculated after determination of free F(ab)2 Y7-B
from the standard curve:
A492/692 = f ([F(ab)2 Y7 − B]) [1]
For each group, the PI values at defined time point were
analyzed and corresponding PI ranges were determined.
Intensity of fluctuations was evaluated according to cal-
culated PI ranges.
Affinity determination by ELISA of IgG
specific for TTd and β2-GP I
The affinities of anti-β2-GP I IgG and anti-TTd IgG to
their Ags were estimated by the use of aqueous solutions
containing different KSCN concentrations. Analysis of the
influence of SCN− on specific sera IgG binding was per-
formed with ELISA-based procedures. The protocol was
similar to those performed for the detection of IgG specific
for TTd and β2-GP I. The unique difference was an addi-
tional incubation of 30 min with KSCN aqueous solutions
after the binding of samples to adsorbed Ag. The aque-
ous solutions containing increasing KSCN concentrations
(0–6 M) were used for Ab desorption. The [SCN−]50%
was calculated for each sample upon linearization of the
corresponding Ag–Ab dissociation profile:
binding(%) = f ([SCN−]) [2]
A preliminary experiment showed that KSCN in the
concentrations used did not induce desorption of coated
β2-GP I or TTd.
Pregnancy-related pathology
Ten-week-old BALB/c mice were immunized with TTd
according to the described protocols (Fig. 1) and mated
after the third TTd dose. Non-treated mice (normal age-
matched controls) were also mated. The date of coitus was
determined by visualization of the vaginal plug (denoted
as the first day of pregnancy). Mice were killed on the
14th day of pregnancy, and macroscopic examination of
the embryos and uterus performed. The NoF as well as
NoFR (a more than 50% reduction in fetal volume) was
determined. The rate of fetal resorption was calculated for
each mouse and expressed as the percentage of the total
number of fetuses:
NoFR × 100/(NoF + NoFR) [3]
Statistical analysis
The statistical significance of immunization-induced fluc-
tuations in a defined Ab pool was determined by a paired
Student’s t-test, using values for corresponding normal
sera collected prior to any intervention as a reference. For
estimation of the TTd-booster dose influence (check point
C), the concentrations of specific Abs at check point B were
used as a reference.
To evaluate the significance of the observed differences
in sera IgG affinity toward TTd and β2-GP I, dissociation
profiles were also compared by a paired Student’s t-test.
Severity of pregnancy-related pathology (resorption
rates, number of fetuses) was evaluated by a t-test for
independent groups. The control group of non-treated
mice was used as a reference.




Concentrations of TTd-specific IgM and IgG were mea-
sured in individual mice sera; their mean concentrations
at defined time points are presented in Figure 2. Analysis of
nc group sera did not show any significant time-dependant
fluctuations within these pools (data not shown).
Anti-TTd IgM
TTd-specific IgM was detected in normal sera collected be-
fore any treatment (mean A492/692 ± SE = 0.243 ± 0.011)
(Fig. 2a). A transient fall in the anti-TTd IgM concen-
tration was recorded in all groups during the course of
immunization (Fig. 2a). During the post-immunization
follow-up period, a slight increase in TTd-specific IgM was
observed in all groups except CFA//TTd/Al. The booster
dose application induced an increase in TTd-specific IgM
concentration in both non-pretreated (P < 0.05) and
CFA//TTd/Al groups.
Anti-TTd IgG
IgG specific for TTd was absent in sera collected prior
to any treatment (mean A492/692 ± SE = 0.064 ± 0.003)
(Fig. 2b). Immunization induced a gradual increase in
the concentration of anti-TTd IgG (predominantly IgG1,
data not shown), and the concentration was significantly
increased in all groups after completion of the immuniza-
tion protocol (check point A).
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Fig. 2. Immunization-induced changes in the pool of IgM (panel a)
and IgG (panel b) specific for TTd. The reactivity of Abs belonging to
the same isotype towards TTd was examined simultaneously in individual
sera. Results are presented as the mean A492/620 ± SE for each group
(n = 15 mice/group) at defined time points. The statistical significance of
immunization-induced fluctuations was determined by a paired Student’s
t-test using the A492/620 for corresponding normal sera (−1 week) as a
reference (P < 0.05∗, P < 0.005∗∗, P < 0.0005∗∗∗). Cut-off values for
detection of IgM and IgG Abs specific for TTd were 0.03 and 0.05,
respectively.
Despite a slight fall observed during the 11-week post-
immunization follow-up period in all TTd/glyc groups
(Fig. 2b), the concentration of anti-TTd IgG remained at
a significantly higher concentration compared with the
corresponding normal sera. In addition, the booster TTd
dose induced an additional anti-TTd IgG increase in those
groups (P < 0.05, compared with the sera taken at check
point B).
In the no//TTd/Al group a sustained increase in anti-
TTd IgG during the post-immunization period was ob-
served, with a maximal level recorded 11 weeks after the
last TTd dose (Fig. 2b). The concentration of anti-TTd
IgG after the booster dose remained unaffected in both
TTd/Al groups.
Anti-TTd IgG affinity
The dissociation profiles of TTd/anti-TTd IgG complexes
in the presence of different KSCN concentrations were
used to estimate affinity of sera anti-TTd IgG toward
TTd. Pools of sera taken at check point A were used
as samples. The linear correlation (R > 0.98) between
[SCN−] and anti-TTd IgG binding was calculated. The
average affinities of anti-TTd IgG, evaluated according to
[SCN−]50%, were higher in sera from TTd/Al–immunized
mice ([SCN−]50%no//TTd/Al = 3.19 M; [SCN−]50%
CFA//TTd/Al = 4.36 M) compared with the correspond-
ing TTd/glyc group under the same pretreatment pro-
tocol ([SCN−]50%no//TTd/glyc = 3.28 M; [SCN−]50%
CFA//TTd/glyc = 3.82 M). As can be seen, IgG Abs with
the highest affinity toward TTd were present in sera from
CFA//TTd/Al–immunized mice. Furthermore, dissocia-
tion profiles of no//TTd/Al and no//TTd/glyc groups were
similar, whereas corresponding CFA-pretreated groups
showed statistically significant differences (P < 0.0005).
Anti-β2-GP I Abs
It has been shown that a variety of stimuli which increase
the potency of T cell stimulation, including high Ag dose
(20), can allow Th cells to escape regulatory T cell mediated
suppression, leading to a break in peripheral tolerance. It
has also been shown (26) that immunization of mice with
multiple TTd doses ranging from 10–50 μg/mice was not
sufficient to induce experimental APS. For these reasons
we decided to use 100 μg TTd/dose in our attempt to
induce autoimmunity by hyper-immunization.
Concentrations of IgM and IgG specific for β2-GP I
in individual mice sera were recorded during the course
of immunization as well as during the post-immunization
period; the mean concentrations at defined time points are
presented in Figure 3. The decision to follow fluctuations
in Abs specific for β2-GP I long after completion of immu-
nization was based on the previously described mouse APS
model, in which a long-term post-immunization increase
in anti-β2-GP I IgG has been reported (27, 28). Addi-
tionally, the concentration of Abs specific for β2-GP I was
examined in sera collected 1 week after the booster TTd
dose application (check point C) to see whether memory
cells specific for β2-GP I had been established.
Preliminary screening showed the presence of IgM
and IgG specific for β2-GP I in normal mouse sera, but
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Fig. 3. Immunization-induced changes in the pool of IgM (panel a)
and IgG (panel b) specific for β2-GP I. The reactivity of Abs belonging
to the same isotype towards β2-GP I was examined simultaneously in
individual sera. Results are presented as the mean A492/620 ± SE for
each group (n = 15 mice/group) at defined time points. The statistical
significance of immunization-induced fluctuations was determined by a
paired Student’s t-test using the A492/620 for corresponding normal sera
(−1 week) as a reference (P < 0.05∗, P < 0.005∗∗). Cut-off values for
detection of IgM and IgG antibodies specific for β2-GP I were 0.03 and
0.07, respectively.
neither pretreatment (CFA) nor adjuvants (Al or glyc) per
se induced an increase in them. In addition, analysis of nc
group sera, as in the case of anti-TTd Abs, did not show
any significant time-dependant fluctuations within IgM
and IgG pools specific for β2-GP I.
Anti-β2-GP I IgM
Mean concentrations of anti-β2-GP I IgM in mouse sera
collected at the main check points and during the course
of immunization are presented in Figure 3a. The results
show a transitional fall in IgM specific for β2-GP I during
the application of all immunization regimes. Compared
with corresponding normal sera, observed decreases in
concentrations of anti-β2-GP I IgM were statistically sig-
nificant in the no//TTd/Al (P < 0.05 after the second TTd
dose) and CFA-pretreated (P < 0.005 after the first TTd
dose) groups. During the post-immunization period, an
increase in IgM specific for β2-GP I was recorded in all
groups except the CFA//TTd/Al, where a slight fall was
observed. The booster TTd dose induced an increase in
the anti-β2-GP I IgM in no//TTd/Al and CFA//TTd/Al
groups, whereas in the TTd/glyc-immunized groups
the concentrations of Abs specific for β2-GP I were
diminished.
Anti-β2-GP I IgG
Measurements of anti-β2-GP I IgG concentrations in in-
dividual mouse sera (Fig. 3b) revealed a transitional fall
during immunization of both pretreated groups. How-
ever, after completion of all immunization protocols, the
concentrations of serum IgG specific for β2-GP I were
higher than those in the corresponding sera taken be-
fore any treatment. During the post-immunization pe-
riod, an additional increase in anti-β2-GP I IgG was
observed in all groups and was more pronounced in
TTd/glyc–immunized mice compared with the corre-
sponding TTd/Al group. For all groups, maximal con-
centrations of IgG specific for β2-GP I, which were sig-
nificantly higher than in the sera collected prior to any
intervention, were detected in samples collected between
the 7th and 11th week of the post-immunization period.
Moreover, the concentrations registered within this in-
terval were not significantly different. Respective to this
observation, the 11th week of the post-immunization pe-
riod was assigned as one of the main check points.
All further described analyses of the anti-β2-GP I IgG
pool were performed at main check points only, with the
use of each group’s normal sera as well as A, B or C pools
as samples.
Fine epitope specificity of anti-β2-GP I IgG
To assess the sera Abs’ fine epitope specificity we simul-
taneously measured serum IgG reactivity with β2-GP I
coated directly onto MaxiSorp plates (β2-GP I system)
and with β2-GP I bound to immobilized PS (PS+β2-GP
I system).
On the basis of the results of our preliminary experi-
ments, which showed the same reactivity of commercially
available mouse anti-human β2-GP I IgG1 (clone 5F7)
in both systems, we used this Ab as a control for coating
equal amounts of β2-GP I (A492/620[PS] = 0.157 ± 0.001;
A492/620[PS+ β2-GP I] = 2.003 ± 0.044; A492/620[β2-GP
I] = 1.993 ± 0.044).
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Fig. 4. Reactivity of IgG from sera of non- and CFA- pretreated
mice immunized with TTd/Al (panel a) or TTd/glyc (panel b) to-
ward β2-GP I (circles) and PS+β2-GP I (triangles). For each group
(n = 15 mice/group), normal, A, B and C sera pools were used as sam-
ples. Analysis of binding to β2-GP I was done simultaneously in β2-GP I
and PS+β2-GP I systems for all samples. All samples were assayed in trip-
licate and mean A492/620 ± SE are presented. Cut-off value for detection
of anti-β2-GP I IgG in both systems was 0.07.
Reactivity of serum IgG toward β2-GP I in systems com-
prising β2-GP I and PS+β2-GP I is presented in Figure 4.
According to results for all groups at each time point, the
reactivity of serum IgG was better for β2-GP I adsorbed
directly onto the microplate. We approximated that the re-
duction of A492/620(PS+β2-GP I) compared with the cor-
responding A492/620(β2-GP I), calculated as a percentage,
was inversely correlated to the contribution of PS+β2-GP
I-specific IgG to the overall anti-β2-GP I IgG pool.
For the pools of normal sera, the reduction of A492/620
values in the PS+β2-GP I system, compared with the β2-
GP I system, was 55.08% ± 0.56%. At check point A, the
reduction of A492/620 in the PS+β2-GP I system was less
pronounced than for the pools of normal sera, indicating
the prevalent synthesis of Abs specific for β2-GP I bound
to immobilized PS. A492/620(PS+β2-GP I) reductions were
greater in the TTd/Al groups (36.96% for no//TTd/Al,
35.00% for CFA//TTd/Al) (Fig. 4a) compared with the
TTd/glyc group that underwent the same pretreatment
(35.29% for no//TTd/glyc, 20.35% for CFA//TTd/glyc)
(Fig. 4b). During the 11-week post-immunization period
the contribution of IgG specific for PS+β2-GP I to the
overall anti-β2-GP I IgG pool remained unaffected in
non-pretreated groups (reductions at check-point B were
34.81% for no//TTd/Al and 36.73% for no//TTd/glyc).
In contrast the CFA-pretreated groups showed a lowering
tendency in anti-PS+β2-GP I IgG (reductions at check-
point B were 38.86% for CFA//TTd/Al and 44.60% for
CFA//TTd/glyc). Finally, although application of the TTd
booster dose did not induce an increase in total IgG spe-
cific for β2-GP I in either group, the contribution of Abs
specific for PS+β2-GP I was higher than that in the cor-
responding pool of normal sera. For sera pools at check
point C, A492/620 values in the PS+β2-GP I system were
from 30.43% (no//TTd/Al) to 47.05% (CFA//TTd/glyc)
lower than corresponding values in the β2-GP I system.
Subclass analysis of anti-β2-GP I IgG
Preliminary screening showed that, irrespective of the ap-
plied immunization protocol, the contribution of indi-
vidual subclasses to total anti-β2-GP I IgG was in the
following order IgG1 > IgG2a > IgG3. The focus was
on IgG1 and IgG2a anti-β2-GP I Abs with respect to 1)
their contribution to the overall anti-β2-GP I IgG pool;
2) the fact that they could be regarded as markers of Th1/
Th2 skewing (24) and 3) their already documented role
in development of pathology related to anti-β2-GP I Abs
(29). The results (Fig. 5) showed the following: First, an
increase in both IgG1 and IgG2a Abs specific for β2-GP I
was induced by application of all immunization protocols
but with specific, context-dependent kinetics. Second, the
increase in IgG1 anti-β2-GP I Abs was more pronounced
during the course of immunization compared with the
post-immunization period (Fig. 5a) when the increase of
IgG2a anti-β2-GP I Abs was predominant (Fig. 5b). Fur-
thermore, an increase in IgG2a Abs specific for β2-GP I
was greater in the TTd/glyc-immunized groups compared
with the corresponding TTd/Al group (Fig. 5b). Finally,
the booster TTd dose did not induce an increase in either
IgG1 or IgG2a Abs specific for β2-GP I (Fig. 5).
Affinity of anti-β2-GP I IgG
The dissociation profiles of β2-GP I/anti-β2-GP I
IgG complexes in the presence of different KSCN
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Fig. 5. Immunization-induced changes in the pool of IgG1 (panel
a) and IgG2a (panel b) specific for β2-GP I. The reactivity of antibodies
belonging to the same IgG subclass towards β2-GP I was examined
simultaneously by using normal, A, B and C sera pools for each group
(n = 15 mice/group) as samples. All samples were assayed in triplicate
and mean A492/620 ± SE are presented. Cut-off values for detection of
IgG1 and IgG2a specific for β2-GP I were 0.07 and 0.05, respectively.
concentrations were used for estimation and compari-
son of mean sera anti-β2-GP I IgG affinity toward β2-GP
I. Comparison of corresponding dissociation profiles and
[SCN−]50% values for normal and check point A pools,
calculated for each pool upon linearization (R > 0.96),
showed that completion of all immunization protocols
induced synthesis of anti-β2-GP I IgG with higher affinity
(P < 0.005) toward β2-GP I. Mean [SCN−]50% for normal
sera pools was 3.81 ± 0.3 M. In contrast to the anti-TTd
IgG, the mean affinities of anti-β2-GP I IgG, estimated ac-
cording to [SCN−]50%, were higher in sera from TTd/glyc–
immunized mice ([SCN−]50%no//TTd/glyc = 4.98 M;
[SCN−]50% CFA//TTd/glyc = 6.01 M) compared with
the TTd/Al group under the same pretreatment pro-
tocol ([SCN−]50%no//TTd/Al = 4.85 M; [SCN−]50%
CFA//TTd/Al = 4.93 M). Finally, a statistically significant
difference in dissociation profiles between identically pre-
treated groups was registered only after CFA pretreatment
(P < 0.0005).
Anti-laminin IgG
Simultaneous analysis of pools for each group compris-
ing sera collected at 2-week intervals showed that in all
groups, except CFA//TTd/Al, slight fluctuations within
the anti-laminin IgG pool were induced (Fig. 6a). In
the CFA//TTd/Al group, more intensive oscillations of
anti-laminin IgG were detected. In the curve representing
time-dependent oscillations of the anti-laminin IgG level,
two peaks were noted in the CFA//TTd/Al group—in sera
pools A and B. Analysis of reactivity toward laminin per-
formed for individual normal sera, as well as sera collected
at check points A and B, confirmed that the concentration
of anti-laminin IgG found 1 week after completion of im-
munization was significantly greater than that in normal
sera (P < 0.05).
Natural antibodies
The influence of the described TTd immunizations on
the natural Abs pool was estimated according to time-
dependent fluctuations in the expression of the natural
idiotope Y7 on the sera IgM (30, 31) (Fig. 6b).
Given that natural Ab concentrations have a wide phys-
iological range (mean PI ± SE of normal sera pools was
52.81 ± 8.99%) and considerable time-dependent oscilla-
tions (PI range for nc was 19.8%), all fluctuations within
a range less than 20% were not considered significant. In
accordance with Y7 expression, the most intensive fluctu-
ations were recorded in the CFA//TTd/Al group (PI range
was 48.91%) (Fig. 6b). In that group two pronounced falls
in serum Y7+ Ig concentration were registered: the first
after completion of immunization and the second after
the booster TTd dose. For all other groups, the PI range
was less than 20%.
Evaluation of pathology related
to anti-β2-GP I Ab
The analysis of pregnancy outcomes (fecundity, num-
ber of fetuses and fetal resorption rate) following TTd-
immunization was used for evaluation of the pathogenic
potential of induced immune responses. This was based
on the following: 1) the role of anti-β2-GP I Abs in genesis
of pregnancy-related pathology has been well documented
(18) and 2) secretion of anti-β2-GP I Abs was induced in
all immunized mice in our experiment.
Results showed that pregnancy outcomes were signifi-
cantly context-dependent, implying different pathological
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Fig. 6. Immunization-induced changes in reactivity of sera IgG
with mouse laminin (panel a), and fluctuations within the natural
Ab pool followed via expression of Y7 idiotope (panel b). The
expression of Y7 idiotope was measured through inhibition of F(ab)2
Y7-B binding to IgM DJ (Y7+ IgM) adsorbed onto plastic in the presence
of defined sera pools (n = 15 mice/group). All samples were assayed in
triplicate and mean A492/620 ± SE (panel a) or mean PI ± SE (panel b)
are presented. Cut-off value for detection of anti-laminin IgG was 0.08.
potentials for the induced immune responses. The results
from two independently performed experiments are pre-
sented in Table 1. A slight decrease in fecundity (number
of the pregnant females) following TTd-immunization,
which was most pronounced in the no//TTd/Al group,
was observed.
Analyses of placentas and fetuses were performed on the
14th day of pregnancy. A reduction in the total number of
fetuses (defined as the sum of NoF and NoFR), as well as an
increased rate of fetal resorption (defined as a more than
50% reduction in fetal volume), was observed. The most
Table 1 Evaluation of pregnancy outcomes in TTd-immunized mice per-
formed on the 14th day of gestation
Treatment Pregnant mice Total number of Fetal resorption‡
type (%)† fetuses‡ (%)
nc 75.00 ± 5.00 9.22 ± 0.54 3.78 ± 1.02
no//TTd/Al 61.77 ± 2.3 9.01 ± 0.39 8.58 ± 2.91
no//TTd/glyc 66.33 ± 3.3 7.02 ± 0.22∗ 5.72 ± 2.08
CFA//TTd/Al 66.45 ± 4.55 6.43 ± 0.52∗ (a) 16.67 ± 3.13∗ (a)
CFA//TTd/glyc 71.71 ± 3.29 5.33 ± 0.31∗∗ 7.53 ± 2.56
†Mean value calculated from two independent experiments (8–10 mice
per group per experiment).
‡Mean fetus number/fetal resorptions ± SE per pregnancy, calculated
for all mice immunized according to same protocol in two independent
experiments.
∗P < 0.05, ∗∗P < 0.005 (t-test for independent groups; nc group was
used as the reference).
aP < 0.05 (comparison of CFA-pretreated groups by t-test for
independent groups).
striking reduction in number of fetuses was detected in
CFA//TTd/glyc–immunized mice. Statistically significant
decreases in the total number of fetuses were also noticed
in the no//TTd/glyc and CFA//TTd/Al groups. When com-
parisons between the experimental groups that underwent
the same pretreatment were performed, a greater fetal
resorption rate was found in TTd/Al–immunized mice.
However, compared with nc mice, only the CFA//TTd/Al
group showed statistically significant increases in fetal re-
sorption. One must note that, in addition to fetal resorp-
tion, placental hemorrhages, accompanied by a lesser de-
gree of reduction in fetal volume, were seen in immunized
pregnant mice but not in nc pregnant mice.
DISCUSSION
Our current research has confirmed that TTd could be an
inducible target for production of Abs specific for β2-GP
I (26) and, more importantly, has described modulation
of the self-reactive immune response in the context of
TTd application, which eventually results in the response
having different pathological potentials.
In this paper, we have reported on three sets of changes
in BALB/c mice sera induced by immunization with high
concentrations of TTd: firstly, changes induced in profiles
of sera IgM and IgG specific for TTd; secondly, changes
in profiles of autoAbs specific for β2-GP I and mouse
laminin; thirdly, changes in the expression of Y7 natural
idiotope.
It is clear that the induced general immune re-
sponse is a result of interplay between the pretreat-
ments and the impact of the adjuvants. CFA is a mixture
of TLR agonists (lipid A, N-acetylmuramyl-L-alanyl-D-
isoglutamine, trehalose-6,6-dimycolate and CpG) (25)
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and possesses a high activation potential. Through its ac-
tion on TLR-2, TLR-4 and TLR-9, CFA activates B and T
cells. Owing to its chemical chaperone potential, glycerol
primarily stimulates T cells (24) while Al is cited in the
literature as a B cell stimulator (23).
Although our focus was on the properties of modulation
of self-directed immune responses, we also analyzed the
TTd-specific immune response in order to reveal the re-
lationship between self-directed and Ag-specific immune
response. In all hyper-immunized mice, irrespective of the
immunization protocol applied, TTd-specific Abs were
induced. The fact that hyper-immunization does not sup-
press Ag-specific immune response (32) but, on the con-
trary, induces its strong stimulation can be explained by
the Th2-predominant genetic background of BALB/c mice
(33) and thus predominant generation of a Th2 response.
Th2 clones, compared to Th1 clones, are more resistant
to activation-induced cell death triggered by high doses of
antigens (34). Relative to the time-dependent changes of
anti-TTd IgG concentrations, TTd immunization resulted
in either a classic adaptive response (TTd/glyc immuniza-
tions) or in the persistence of high concentrations of serum
Abs (TTd/Al immunizations). Moreover, a comparison of
the groups pretreated in the same way indicates that use
of Al as adjuvant has a positive impact on anti-TTd IgG
affinity.
Concurrent with the TTd-directed immune response,
a self-reactive immune response was also induced in all
groups. The anti-β2-GP I Abs detected after completion of
immunization could be the result of perturbation within
the naturally occurring Abs pool or a part of the TTd-
specific Abs generated from molecular mimicry. Because
of structural homology between TTd and β2-GP I, the
observed post-immunization increase in IgG with spe-
cific affinity for β2-GP I indicates that a T cell–dependent
component of the self-reactive response is most probably
activated. Moreover, curves of the same shape, as observed
in the TTd/Al groups, represent fluctuations in Abs spe-
cific for TTd and β2-GP I and stress the importance of
the overlap between these Abs. In contrast, the glycerol-
induced segregation of the humoral immune response
specific for TTd and β2-GP I may be a consequence of a
pronounced Ag-specific T cell–dependent branch in both
TTd/glyc groups.
When we consider anti-β2-GP I Abs, the following facts
must be kept in mind (18): 1) Anti-β2-GP I Abs occur in
normal sera as part of the natural Ab pool exerting a
homeostatic role. 2) Anti-β2-GP I Abs comprise a mix-
ture of Abs specific for constitutively exposed epitopes on
the surface of β2-GP I, as well as Abs specific for cryp-
tic epitopes (35) uncovered following β2-GP I adsorp-
tion to a negatively charged surface (like PS). 3) Effector
functions and pathological potential of anti-β2-GP I Abs
depend on their concentration, affinity and fine epitope
specificity.
Correlation of pregnancy outcomes with the results of
performed serological tests implies that concentration of
total anti-β2-GP I Abs per se is an important (as concentra-
tion of total anti-β2-GP I Abs was higher following immu-
nization than in normal sera) but not the primary factor in
pathology induction (the lowest level was recorded in the
CFA//TTd/Al group). Our results show that the severity of
pathology can be correlated to parameters which could be
connected to direct Abs binding: 1) the abundance of IgG
that recognized β2-GP I following interaction with PS and
2) IgG affinity. Although a clear correlation between the
concentration of complement fixing Abs (IgG2a and IgM)
and severity of pathology was not observed, the greatest
abundance of IgG2a within the overall anti-β2-GP I IgG
(revealed according to A492/620 [IgG1]/A492/620 [IgG2a]) in
the sera of CFA//TTd/glyc mice implies their importance
in genesis of pathology. In addition, given that IgG2a is a
hallmark of Th1 response (24), it would seem that skewing
of the immune response in a Th1 direction would be more
deleterious.
By analyzing the mutual relationship of serum IgG re-
activity in β2-GP I and PS+β2-GP I systems we approx-
imated the concentration of Abs specific for cryptic epi-
topes on β2-GP I. These Abs could account for smaller
differences between A492/620 values obtained in the β2-
GP I and PS+β2-GP I systems for sera pools A, B and
C than in corresponding normal sera pools. We assumed
that observed pregnancy pathology was a result of induced
anti-PS+β2-GP I Abs targeting trophoblast (36) and fe-
tus (37). Apoptosis as a normal process during placental
formation (38) and fetal development (37) lead to the
creation of one PS-rich surface that allows formation of
numerous PS+β2-GP I complexes. Furthermore, it has
been documented that numerous trophoblast properties
and functions are negatively affected (defective invasive-
ness and hormone secretion, impaired embryonic implan-
tation, infarctions) by direct anti-β2-GP I Abs binding
and/or concomitant complement activation, resulting in
various complications of pregnancy (reduced fecundity
and number of fetuses, increased fetal resorption rate)
(18, 39–41).
The necessity to use β2-GP I in quite a high concentra-
tion (10 μg/ml) for detection of anti-β2-GP I Abs, thus
allowing its multivalent binding, implies that these Abs
recognize specific Ags with low affinity. Comparison of
[SCN−]50% for normal sera pools and for A sera pools
shows that all immunization protocols induced an increase
in mean affinity of anti-β2-GP I/β2-GP I interactions, this
being higher in CFA-pretreated groups. However, as we
measured affinity in a system using a high-salt concentra-
tion, we must remember anti-cryptic epitope Ab/cryptic
98 c© 2008 The Societies and Blackwell Publishing Asia Pty Ltd
Tetanus toxoid and humoral response
epitope interactions. Namely, it has been demonstrated
that not only interaction of β2-GP I with a negatively
charged surface, but also high ionic strength, can expose
cryptic epitope on β2-GP I in solution (42). So, it may be
more correct to say that higher [SCN−]50% values for A
sera pools are a consequence of affinity maturation within
the anti-β2-GP I IgG pool and/or more abundant IgG
specific for cryptic epitopes on β2-GP I than in normal
sera.
A complex Ag that includes an adjuvant could be ex-
pected to promote all forms of immune responses (innate,
T dependent, T independent), with each response having
a specific contribution. The increase in concentration of
IgM detected after the TTd boost implies activation of in-
nate immunity-based T cell–independent response in all
groups except CFA//TTd/glyc. However, the intense fluc-
tuation in the expression of natural Y7 idiotope shows that
its involvement in shaping of overall immune response is
most pronounced in the CFA//TTd/Al group. In regard to
the reduction in number of fetuses observed in the CFA-
pretreated groups, involvement of innate immunity has
a positive impact, making an overall immune response
less deleterious. However, in regard to the high resorption
rate observed in the CFA//TTd/Al group, it could be hy-
pothesized that epitope spreading and affinity maturation
within the natural Abs pool results in a harmful immune
response. Furthermore, it is interesting to compare time-
dependent fluctuations within the anti-laminin IgG pool
with Y7 expression. A decrease in percentage of Y7+ nat-
ural Abs was detected immediately after an increase in the
concentration of IgG specific for mouse laminin, and co-
incided with an increase in anti-β2-GP I IgG. Noting that
anti-laminin Abs possess a high pathological potential in
murine systems (17), one could regard the decrease in nat-
ural Y7 idiotope expression as an attempt by the system
to roll back to a steady state, using a natural Abs pool as
the basis. However, the suppression of one autoimmune
response (anti-laminin Abs) was accompanied by activa-
tion of another one (anti-β2-GP I), a feature that has been
referred to as the “kaleidoscope of autoimmunity” (43).
We have convincingly demonstrated that the border
between autoimmunity and overt autoimmune disease
is very narrow, and is dependent on the context of the
triggering Ag application. Molecular mimicry, which re-
sults in generation of anti-β2-GP I Abs on TTd immu-
nization, is necessary, but not sufficient in itself, for the
development of severe pathology. The existence of ad-
ditional triggering events, as determined by the context
of the Ag application, also seems to be necessary. In the
context of APS, activation of T cells seems to be crit-
ical, since induction of statistically significant pathology
was observed following TTd application in contexts which
provided their activation (glycerol and/or CFA). Further-
more, the more pronounced pregnancy-related pathology
in the CFA-pretreated groups implies a role of activation
via TLRs.
We suggest that examination of immune responses in-
duced by micAg applied in different contexts could be use-
ful for defining additional signals and mechanisms which
lead to autoimmunity-autoimmune disease conversion.
Analysis of autoAbs pool characteristics (affinity, isotypic
profile, fine epitope specificity and concentration) could
be useful for prediction of the pathological potential of
induced immune responses. Finally, in the context of an
APS study, this model could be regarded a new model sys-
tem. Although the importance of micAg in APS etiology
has been clearly demonstrated, currently described mod-
els are based on APS induction by β2-GP I, peptides that
share structural homology with β2-GP I or specific Ab
immunization (reviewed in 44).
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